EUVIMEDEUVIMED entdecken
Crossref

Polymeric Nanoparticles Simultaneously Delivering Paclitaxel Prodrug and Combretastatin A4 with Exceptionally High Drug Loading for Cancer Combination Therapy

Huicong Zhou, Zhaofan Yang, Guanyu Jin, Lanqing Wang, Yuanzhen Su, Hao Liu, Hai Sun, Lingwei Xue iD, Liwei Mi iD, Irina A Veselova, Mingqiang Li iD, Shixian Lv und 1 weitere

Nano Letters · 05.03.2025 · 25 (9) · 3479-3488

DOI: 10.1021/acs.nanolett.4c05863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, online erschienen am 24.02.2025. Verfasst von Huicong Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Gua…. Hauptthemen laut MEDLINE: Paclitaxel, Prodrugs, Nanoparticles, Stilbenes. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science Fund for Distinguished Young Scholars of Guangdong Province, Guangzhou Municipal Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomedicines capable of delivering multiple drugs have become essential in combination therapy. However, the challenges of low drug loading capacity (DLC) and difficulties in administering dosages between different drugs significantly limit the antitumor efficacy. In this study, a nanomedicine constructed through a rational prodrug and nanocarrier design was reported for cancer combination therapy. Initially, a phenylborate ester (PBE) group-modified paclitaxel (PTX) prodrug (PTX-PBE) was synthesized and could self-assemble in water. Subsequently, combretastatin A4 (CA4) polymer conjugates, mPEG-PCA4 (PCA4), were synthesized as nanocarriers to facilitate the exceptionally high drug loading of PTX-PBE in a precisely controlled manner. Both the in vitro and in vivo experiments demonstrated that the PCA4 loading PTX-PBE nanoparticles (PCA4/PTX-PBE NPs) exhibited potent antitumor efficacy and favorable biocompatibility. Our approach provides a straightforward, efficient, and controllable strategy for the co-delivery of pharmaceuticals in clinical cancer combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelProdrugsNanoparticlesStilbenesNeoplasmsDrug CarriersHumansAnimalsMiceCell Line, TumorPolymersAntineoplastic Agents, Phytogenic

Stichwörter der Autor:innen

Combination therapyCombretastatin A4High drug loadingNanocarrierPaclitaxel prodrug

Substanzen

PaclitaxelProdrugsfosbretabulinStilbenesDrug CarriersPolymersAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, China.
  • School of Materials Science and Engineering, Peking University, Beijing 100871, China.
  • The Central Laboratory, Peking University School and Hospital of Stomatology, Beijing 100081, China.
  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China.
  • Yaoshan laboratory, Pingdingshan University, Pingdingshan, Henan 467000, China.
  • Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia.

ORCID-Profile: Lingwei Xue, Liwei Mi, Mingqiang Li, Xuesi Chen

Förderung

  • National Key Research and Development Program of China
  • Science Fund for Distinguished Young Scholars of Guangdong Province
  • Guangzhou Municipal Science and Technology Project
  • National Natural Science Foundation of China
  • Education Department of Jilin Province
  • Fundamental Research Funds for the Central Universities, Peking University
  • Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund Project
  • Yaoshan laboratory

Zitieren

APA

Zhou, H., Yang, Z., Jin, G., Wang, L., Su, Y., Liu, H., Sun, H., Xue, L., Mi, L., Veselova, I. A., Li, M., Lv, S., & Chen, X. (2025). Polymeric Nanoparticles Simultaneously Delivering Paclitaxel Prodrug and Combretastatin A4 with Exceptionally High Drug Loading for Cancer Combination Therapy. Nano Letters, 25(9), 3479-3488. https://doi.org/10.1021/acs.nanolett.4c05863

Vancouver

Zhou H, Yang Z, Jin G, Wang L, Su Y, Liu H, et al. Polymeric Nanoparticles Simultaneously Delivering Paclitaxel Prodrug and Combretastatin A4 with Exceptionally High Drug Loading for Cancer Combination Therapy. Nano Letters. 2025;25(9):3479-3488. doi:10.1021/acs.nanolett.4c05863

BibTeX
@article{Zhou2025,
  author = {Zhou, Huicong and Yang, Zhaofan and Jin, Guanyu and Wang, Lanqing and Su, Yuanzhen and Liu, Hao and Sun, Hai and Xue, Lingwei and Mi, Liwei and Veselova, Irina A and Li, Mingqiang and Lv, Shixian and Chen, Xuesi},
  title = {Polymeric Nanoparticles Simultaneously Delivering Paclitaxel Prodrug and Combretastatin A4 with Exceptionally High Drug Loading for Cancer Combination Therapy},
  journal = {Nano Letters},
  year = {2025},
  volume = {25},
  number = {9},
  pages = {3479--3488},
  doi = {10.1021/acs.nanolett.4c05863}
}
Kostenlos starten →